CR20230211A - Derivados de ciclopentatiofen carboxamida como antagonistas del receptor del factor de activación de plaquetas - Google Patents

Derivados de ciclopentatiofen carboxamida como antagonistas del receptor del factor de activación de plaquetas

Info

Publication number
CR20230211A
CR20230211A CR20230211A CR20230211A CR20230211A CR 20230211 A CR20230211 A CR 20230211A CR 20230211 A CR20230211 A CR 20230211A CR 20230211 A CR20230211 A CR 20230211A CR 20230211 A CR20230211 A CR 20230211A
Authority
CR
Costa Rica
Prior art keywords
factor receptor
cyclopentathiophene
activating factor
platelet activating
receptor antagonists
Prior art date
Application number
CR20230211A
Other languages
English (en)
Inventor
Dieter Wiedenmayer
Marina Kristina Willwacher
Christofer Siegfried Tautermann
Ferenc Kontes
Matthias Eckhardt
Leo Thomas
Juergen Prestle
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CR20230211A publication Critical patent/CR20230211A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Ciclopentatiofen carboxamidas de la Fórmula (I.0)en donde R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup> y n son como se definen en la descripción y las reivindicaciones, y las sales de este aceptables desde el punto de vista farmacéutico pueden usarse en métodos para el tratamiento de enfermedades que pueden estar influenciadas por antagonizar la actividad mediada por el receptor del factor de activación de plaquetas. <img alt="" src="data:image/png;base64,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 (***)
CR20230211A 2020-11-16 2021-11-12 Derivados de ciclopentatiofen carboxamida como antagonistas del receptor del factor de activación de plaquetas CR20230211A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20207719 2020-11-16
PCT/EP2021/081459 WO2022101377A1 (en) 2020-11-16 2021-11-12 Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists

Publications (1)

Publication Number Publication Date
CR20230211A true CR20230211A (es) 2023-07-13

Family

ID=73543025

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230211A CR20230211A (es) 2020-11-16 2021-11-12 Derivados de ciclopentatiofen carboxamida como antagonistas del receptor del factor de activación de plaquetas

Country Status (17)

Country Link
US (2) US11766443B2 (es)
EP (1) EP4244229A1 (es)
JP (2) JP7465368B2 (es)
KR (1) KR20230109692A (es)
CN (2) CN116745300A (es)
AR (1) AR124070A1 (es)
AU (1) AU2021379248A1 (es)
CA (1) CA3200710A1 (es)
CL (2) CL2023001361A1 (es)
CO (1) CO2023005894A2 (es)
CR (1) CR20230211A (es)
DO (1) DOP2023000090A (es)
EC (1) ECSP23036210A (es)
IL (1) IL302769A (es)
MX (1) MX2023005678A (es)
TW (1) TW202237620A (es)
WO (1) WO2022101377A1 (es)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3502392A1 (de) 1985-01-25 1986-07-31 Boehringer Ingelheim KG, 6507 Ingelheim Neue thieno-triazolo-1,4-diazepino-2- carbonsaeureamide, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen
PH30676A (en) * 1986-07-22 1997-09-16 Boehringer Ingelhein Kg Hetrazepine compounds which have useful pharmaceutical utility
DE3909012A1 (de) 1989-03-18 1990-09-20 Boehringer Ingelheim Kg Verbessertes verfahren zur herstellung von enantiomerenreinen hetrazepinen
DE4010528A1 (de) 1990-04-02 1991-10-17 Boehringer Ingelheim Kg Praeparativ chromatographisches trennverfahren zur herstellung enantiomerenreiner hetrazepine
DE4132763A1 (de) 1991-10-02 1993-04-08 Boehringer Ingelheim Kg Verbessertes verfahren zur herstellung von enantiomerenreinen saeureamiden hetrazepinoider struktur
FR2779652B1 (fr) 1998-06-15 2001-06-08 Sod Conseils Rech Applic Utilisation de diazepines pour la preparation de medicaments destines a traiter les etats pathologiques ou les maladies dans lesquels un des recepteurs de la somatostatine est implique
US20050032713A1 (en) * 2002-03-27 2005-02-10 Wurtman Richard J. Platelet-activating factor antagonists as analgesic, anti-inflammatory, uterine contraction inhibiting, and anti-tumor agents
CA2670031A1 (en) 2006-11-20 2008-05-29 Alantos Pharmaceuticals Holding, Inc. Heterobicyclic metalloprotease inhibitors

Also Published As

Publication number Publication date
ECSP23036210A (es) 2023-06-30
CO2023005894A2 (es) 2023-05-29
EP4244229A1 (en) 2023-09-20
JP2023521200A (ja) 2023-05-23
WO2022101377A1 (en) 2022-05-19
KR20230109692A (ko) 2023-07-20
CN117624188A (zh) 2024-03-01
TW202237620A (zh) 2022-10-01
CL2023001361A1 (es) 2023-11-03
CA3200710A1 (en) 2022-05-19
MX2023005678A (es) 2023-05-26
AR124070A1 (es) 2023-02-08
AU2021379248A1 (en) 2023-06-22
IL302769A (en) 2023-07-01
AU2021379248A9 (en) 2024-10-10
CN116745300A (zh) 2023-09-12
US20220160725A1 (en) 2022-05-26
US11766443B2 (en) 2023-09-26
JP2024099528A (ja) 2024-07-25
CL2024000317A1 (es) 2024-07-12
DOP2023000090A (es) 2023-06-15
JP7465368B2 (ja) 2024-04-10
US20230355638A1 (en) 2023-11-09

Similar Documents

Publication Publication Date Title
PH12017501140A1 (en) TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
PH12020551315A1 (en) Benzoxazepin oxazolidinone compounds and methods of use
TN2019000110A1 (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
PH12018500532A1 (en) 8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4,5-c]quinolin-2- one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer
ZA202204929B (en) Rimegepant for cgrp related disorders
PH12020550503A1 (en) Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors
MX2018009257A (es) Derivados de benzimidazol como moduladores de ror-gamma.
SG10201808053XA (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
PH12021551196A1 (en) 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use
WO2020115555A3 (en) Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
MX2021002321A (es) Nuevos metodos.
MX2021010888A (es) Derivados heteroaromaticos y aromaticos heterobiciclicos para el tratamiento de trastornos relacionados con ferroptosis.
MX2022006086A (es) Derivados de piridopirimidinona como antagonistas de ahr.
PH12019500497A1 (en) Heteroaryl carboxamide compounds as inhibitors of ripk2
MX2020010618A (es) Derivados de pirazolotriazolopiriminina como antagonista del receptor a2a.
EA202090383A1 (ru) Усовершенствованный способ получения производных аминопиримидина
MX2021004883A (es) Metodos y composiciones para tratar apnea del sue?o.
MX2024007058A (es) Derivados de 5,6,7,8-tetrahidro-2,6-naftiridina como terapeuticos contra el cancer.
MX2019013148A (es) Compuestos heterociclicos biciclicos sustituidos como inhibidores de la nadph oxidasa.
MX2021006012A (es) Derivados de amino triazolo quinazolina 7-, 8-, y 10-sustituidos como antagonistas de receptor de adenosina, composiciones farmaceuticas y su uso.
EA201892529A1 (ru) Комбинация чистых антагонистов 5-htрецепторов с ингибиторами ацетилхолинэстеразы
MX2018011592A (es) Compuesto que tiene actividad inhibitoria de idh mutante, metodo de preparacion y usos del mismo.
CR20230211A (es) Derivados de ciclopentatiofen carboxamida como antagonistas del receptor del factor de activación de plaquetas
NZ747797A (en) Triple combination of pure 5-ht6 receptor antagonists, acetylcholinesterase inhibitors and nmda receptor antagonist
MX2021000966A (es) Piridopirimidinas como inhibidores del receptor de histamina h4.